跳至主要内容
临床试验/CTRI/2022/02/039947
CTRI/2022/02/039947已完成不适用

Evaluation of dermatological safety of test products by primary irritation patch test on healthy human volunteers of varied skin types

Arbro pharmaceutical Pvt Ltd1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2022年7月2日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
Safety assessment of investigational products for

研究概览

简要总结

Objective:

The objective of this study is to evaluate the dermatological safety of the investigational products on healthy human subjects. A primary irritation patch test is used widely for the evaluation of the safety of cosmetics in humans.

Sample Size: Twenty four (male and female, in a nearly equal ratio of 1:1) adult subjects in the age group of 18 years to 55 years (both inclusive)

Primary skin irritation results from reversible inflammatory changes in the skin following the application of a test substance.

By this test, irritation potential of a substance is assessed by a single application of patch under complete occlusion for 24 hrs and is done as per BIS standard (BIS4011:2018)

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 55.00 Year(s)(—)
性别
All

入选标准

  • 1.Healthy male and female subjects in the age group of 18-55 years(both age inclusive)
  • Subject is having valid proof of identity and age
  • Subjects with skin phototype III to V 4.Subject is having apparently healthy skin on test area 5.Subject representing normal, oily, dry and combination skin type in nearly equal ratio
  • Subject willing to give a voluntary written informed consent
  • Subject willing to maintain the test patches in designated positions for 24 Hours
  • Subject willing to come for regular follow up visits
  • Subject ready to follow instructions during the study period
  • Subject without any open wounds, cuts, abrasions, irritation symptoms.

排除标准

  • Subjects with Known hypersensitivity to any of the study products or constituents
  • Subjects having any significant pathology in the test area
  • Subjects with any kind of skin allergy, antecedents or cutaneous disease which may influence the study results
  • Subjects having topical or systemic treatment in last month prior to participation in the study and during the study that could interfere with the study treatments/ assessments
  • Athletes and subjects with history of excessive sweating
  • Subject is Pregnant or Lactating
  • Subject with any significant medical condition that would interfere with the participation in the trial
  • Subjects participated in any other cosmetic or therapeutic trial or in a similar investigation
  • Subject is having Scars, excessive terminal hair or tattoo on the studied area.

结局指标

主要结局

Safety assessment of investigational products for

时间窗: Safety assessment of investigational products for | irritation potential using Draize scale after patch | removal at day 3, day 4 and 7 days post patch removal.

irritation potential using Draize scale after patch

时间窗: Safety assessment of investigational products for | irritation potential using Draize scale after patch | removal at day 3, day 4 and 7 days post patch removal.

removal at 0 hours(day 3),24 hours(day 4) and 7 days post

时间窗: Safety assessment of investigational products for | irritation potential using Draize scale after patch | removal at day 3, day 4 and 7 days post patch removal.

patch removal.

时间窗: Safety assessment of investigational products for | irritation potential using Draize scale after patch | removal at day 3, day 4 and 7 days post patch removal.

次要结局

未报告次要终点

研究者

发起方
Arbro pharmaceutical Pvt Ltd
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验